BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
INCY upcoming catalysts
Incyte Corporation: 3 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 18 readout(s) and 4 FDA event(s). Subscribe to INCY (.ics).
Drugs: Povorcitinib, Ruxolitinib, INCB099280, Lenalidomide, Cyclophosphamide, Doxorubicin, Prednisone, ICS-LABA, INCA034176, ibrutinib, Axatilimab, Corticosteroids, Rituximab, Vincristine, Retifanlimab, Dexamethasone, Methotrexate, Osimertinib
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P2 | Incyte Corporation INCY | NCT05851443 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Moderate to Severe Asthma | active not recruiting | 247 |
| 2026-12-26 est. | P3 | Incyte Corporation INCY | NCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | active not recruiting | 617 |
| 2027-01-06 est. | P1/P2 | Incyte Corporation INCY | NCT06843408 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | Chronic Graft-versus-host-disease | active not recruiting | 32 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-05-18 | FDA approval | approved | INCYTE CORP INCY | ZYNYZ | Approved 2026-05-18: ZYNYZ (BLA761334 SUPPL9) |
| 2026-05-01 | FDA approval | approved | INCYTE CORP INCY | JAKAFI | Approved 2026-05-01: JAKAFI XR (NDA217180 ORIG1) |
| 2026-03-30 | FDA approval | approved | INCYTE CORP INCY | ZYNYZ | Approved 2026-03-30: ZYNYZ (BLA761334 SUPPL8) |
| 2025-12-17 | FDA approval | approved | INCYTE CORP INCY | ZYNYZ | Approved 2025-12-17: ZYNYZ (BLA761334 SUPPL5) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-05 est. | P2 | Incyte Corporation INCY | NCT04509700 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | B-Cell Malignancies | active not recruiting | 112 |
| 2026-10-29 | P3 | Incyte Corporation INCY | NCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Hidradenitis Suppurativa | active not recruiting | 580 |
| 2026-10-19 est. | P3 | Incyte Corporation INCY | NCT06516952 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | Prurigo Nodularis | active not recruiting | 349 |
| 2026-10-01 | P3 | Incyte Corporation INCY | NCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Hidradenitis Suppurativa | active not recruiting | 573 |
| 2026-10-01 | P2 | Incyte Corporation INCY | NCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | active not recruiting | 130 |
| 2026-09-30 | P2 | Incyte Corporation INCY | NCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Advanced Solid Tumor | terminated | 73 |
| 2026-09-28 | P3 | Incyte Corporation INCY | NCT06516965 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | Prurigo Nodularis | active not recruiting | 346 |
| 2026-09-28 | P2 | Incyte Corporation INCY | NCT05888844 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | terminated | 63 |
| 2026-09-01 est. | P3 | Incyte Corporation INCY | NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | Diffuse Large B-cell Lymphoma | active not recruiting | 899 |
| 2026-08-07 | P3 | Incyte Corporation INCY | NCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 159 |
| 2026-07-29 | P1/P2 | Incyte Corporation INCY | NCT06873789 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | Solid Tumors; Advanced Solid Tumors; Metastatic Solid Tumors | terminated | 9 |
| 2026-05-29 | P2 | Incyte Corporation INCY | NCT04463771 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Wh | Endometrial Cancer | completed | 206 |
| 2026-05-11 | P2 | Incyte Corporation INCY | NCT04640025 A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib | Myelofibrosis; Postlung Transplant (Bronchiolitis Obliterans); Chronic Graft Versus Host Disease | terminated | 18 |
| 2026-03-30 | P3 | Incyte Corporation INCY | NCT05429268 Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma | active not recruiting | 82 |
| 2026-03-17 | P3 | Incyte Corporation INCY | NCT06113471 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | NonSegmental Vitiligo | active not recruiting | 450 |
| 2026-03-03 | P2 | Incyte Corporation INCY | NCT02723994 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | Leukemia | completed | 171 |
| 2026-02-24 | P3 | Incyte Corporation INCY | NCT06113445 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | NonSegmental Vitiligo | active not recruiting | 467 |
| 2025-12-24 | P1/P2 | Incyte Corporation INCY | NCT02917993 An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | Lung Cancer | completed | 59 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.